FDx Advisors Inc. lowered its position in Insulet Co. (NASDAQ:PODD) by 29.2% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 4,034 shares of the medical instruments supplier’s stock after selling 1,666 shares during the quarter. FDx Advisors Inc.’s holdings in Insulet were worth $278,000 as of its most recent SEC filing.
Other institutional investors have also recently modified their holdings of the company. Cerebellum GP LLC purchased a new position in Insulet in the fourth quarter worth approximately $122,000. Equitec Specialists LLC purchased a new position in Insulet in the fourth quarter worth approximately $145,000. C M Bidwell & Associates Ltd. purchased a new position in Insulet in the fourth quarter worth approximately $188,000. Diversified Trust Co acquired a new stake in Insulet during the fourth quarter worth approximately $218,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in Insulet by 42.6% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,283 shares of the medical instruments supplier’s stock worth $227,000 after purchasing an additional 981 shares in the last quarter.
In related news, Director David A. Lemoine sold 641 shares of Insulet stock in a transaction on Tuesday, March 6th. The shares were sold at an average price of $76.81, for a total value of $49,235.21. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, COO Shacey Petrovic sold 1,319 shares of Insulet stock in a transaction on Tuesday, March 6th. The shares were sold at an average price of $76.81, for a total transaction of $101,312.39. The disclosure for this sale can be found here. Insiders own 2.60% of the company’s stock.
Shares of Insulet Co. (NASDAQ PODD) traded down $0.22 during trading on Wednesday, hitting $84.52. 592,748 shares of the stock were exchanged, compared to its average volume of 519,407. The firm has a market cap of $4,855.21, a PE ratio of -183.74 and a beta of 1.56. Insulet Co. has a fifty-two week low of $38.43 and a fifty-two week high of $85.44. The company has a quick ratio of 5.85, a current ratio of 6.24 and a debt-to-equity ratio of 3.57.
Insulet (NASDAQ:PODD) last announced its earnings results on Wednesday, February 21st. The medical instruments supplier reported ($0.12) EPS for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.04). The business had revenue of $130.50 million during the quarter, compared to analyst estimates of $125.16 million. Insulet had a negative net margin of 5.79% and a negative return on equity of 29.73%. The business’s revenue was up 26.0% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.16) earnings per share. equities analysts expect that Insulet Co. will post -0.3 EPS for the current year.
PODD has been the topic of a number of research analyst reports. Barclays reissued a “buy” rating and set a $78.00 price objective on shares of Insulet in a report on Wednesday, December 13th. Oppenheimer set a $82.00 price objective on shares of Insulet and gave the stock a “hold” rating in a report on Thursday, February 22nd. BidaskClub cut shares of Insulet from a “buy” rating to a “hold” rating in a report on Saturday, December 2nd. UBS Group raised shares of Insulet from a “market perform” rating to an “outperform” rating in a report on Monday, January 8th. Finally, Zacks Investment Research cut shares of Insulet from a “hold” rating to a “sell” rating in a report on Tuesday, January 9th. Eight analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. The stock has an average rating of “Buy” and an average target price of $73.24.
Insulet Company Profile
Insulet Corporation is engaged in the development, manufacturing and sale of the OmniPod Insulin Management System (the OmniPod System), an insulin delivery system for people with insulin-dependent diabetes. The Omnipod System features a self-adhesive disposable tubeless Omnipod device, which is worn on the body for approximately three days at a time and its wireless companion, the handheld Personal Diabetes Manager (PDM).
Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.